July 29th 2025
Oncology nurses can ensure patients with non–small cell lung cancer receive the optimal treatment quickly by understanding comprehensive genomic profiling.
Adagrasib Elicits Intracranial Response in NSCLC With KRAS G12C Mutations, Untreated CNS Metastases
July 17th 2023Findings from the phase 1b cohort of the KRYSTAL-1 trial underscore the intracranial permeation of the KRAS G12C inhibitor adagrasib for patients with non–small cell lung cancer with untreated central nervous system metastases.
Pembrolizumab, In Addition To Chemotherapy, Misses Mark in TKI-Resistant, EGFR+ NSCLC
June 7th 2023Numerical, but not statistically significant, improvements in survival were observed in patients with TKI-resistant, EGFR-mutated, metastatic nonsquamous non–small cell lung cancer who received pembrolizumab to pemetrexed and platinum-based chemotherapy.
Aumolertinib Plus SRT Achieves Intracranial Responses in Oligometastatic EGFR+ NSCLC
May 10th 2023Prospective phase 2 data demonstrated that aumolertinib, followed by salvage stereotactic radiation therapy, elicited responses in patients with intracranial oligometastatic EGFR-mutant non–small cell lung cancer.